M&T Bank
TVRD

M&T Bank’s Tvardi Therapeutics TVRD Stock Holding History

M&T Bank’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-338
Closed -$20.7K – 1678
2023
Q3 		$20.7K Buy
338
+9
+3% +$844 ﹤0.01% 1543
2023
Q2 		$33.4K Buy
+329
New +$45.3K ﹤0.01% 1574

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

M&T Bank's TVRD Position: Q4 2023 in Review

M&T Bank sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 338 shares — an estimated $20.7K sold.

M&T Bank first reported a position in TVRD in Q2 2023 and held it in 2 quarters. The position peaked at $33.4K in Q2 2023. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • M&T Bank reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • M&T Bank sold 338 Tvardi Therapeutics shares in Q4 2023, an estimated $20.7K.
  • M&T Bank first reported a position in Tvardi Therapeutics in Q2 2023 and held it in 2 quarters.
  • M&T Bank's Tvardi Therapeutics position peaked at $33.4K in Q2 2023.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on M&T Bank's 13F filing for Q4 2023, filed 6 Feb 2024.